• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Around $10M Bet On This Tech & Telecom Stock? Check Out These 3 Stocks Insiders Are Buying

    7/12/24 8:42:36 AM ET
    $AHH
    $FBIO
    $FRD
    $LGF
    Real Estate
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHH alert in real time by email

    Although U.S. stocks closed mostly lower on Thursday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform.

    Lions Gate Entertainment

    • The Trade: Lions Gate Entertainment Corp. (NYSE:LGF) 10% owner Steven T Mnuchin acquired a total of 1,129,609 shares at an average price of $8.81. To acquire these shares, it cost around $9.96 million.
    • What's Happening: On June 25, Lionsgate has chosen Amagi to be its partner for FAST playout and deliveries globally.
    • What Lions Gate Entertainment Does: Lions Gate Entertainment, incorporated in 1986, engages in the film, television, subscription, and location-based entertainment businesses in the United States, Canada, and internationally.

    Fortress Biotech

    • The Trade: Fortress Biotech, Inc (NASDAQ:FBIO) President, CEO and Chairman Lindsay A MD Rosenwald acquired a total of 5,000 shares at an average price of $7.39. To acquire these shares, it cost around $36,971.
    • What's Happening: On July 5, Fortress Biotech reported a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
    • What Fortress Biotech Does: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products.

    Don’t forget to check out our premarket coverage here

    Armada Hoffler Properties

    • The Trade: Armada Hoffler Properties, Inc. (NYSE:AHH) Director Dennis H. Gartman bought a total of 4,500 shares at an average price of $11.09. To acquire these shares, it cost around $49,926.
    • What's Happening: Armada Hoffler is expected to report its earnings for the quarter ending June 30, 2024 on Wednesday, Aug. 7.
    • What Armada Hoffler Properties Does: Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States.

    Friedman Industries

    • The Trade: Friedman Industries, Incorporated (NYSE:FRD) Director Joe L Williams bought a total of 3,000 shares at an average price of $14.34. The insider spent around $43,020 to buy those shares.
    • What's Happening: On June 26, Friedman Industries declared a cash dividend of 4 cents per share.
    • What Friedman Industries Does: Friedman Industries Inc is engaged in the manufacturing and processing of steel products.

    Check This Out:

    • S&P 500 Falls Following June Inflation Data: Fear & Greed Index Moves To ‘Neutral’ Zone
    Get the next $AHH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHH
    $FBIO
    $FRD
    $LGF

    CompanyDatePrice TargetRatingAnalyst
    Armada Hoffler Properties Inc.
    $AHH
    6/27/2025$8.00Buy
    Jefferies
    Armada Hoffler Properties Inc.
    $AHH
    1/28/2025$11.00Sector Perform
    Scotiabank
    Armada Hoffler Properties Inc.
    $AHH
    7/15/2024$13.00 → $11.00Buy → Hold
    Jefferies
    Armada Hoffler Properties Inc.
    $AHH
    7/15/2024$12.75Buy
    Stifel
    Fortress Biotech Inc.
    $FBIO
    3/15/2024$10.00Buy
    ROTH MKM
    Fortress Biotech Inc.
    $FBIO
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    Armada Hoffler Properties Inc.
    $AHH
    10/25/2021$14.00 → $13.50Neutral → Underperform
    BofA Securities
    Armada Hoffler Properties Inc.
    $AHH
    9/22/2021$15.00Buy
    Stifel
    More analyst ratings

    $AHH
    $FBIO
    $FRD
    $LGF
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Armada Hoffler Properties Inc.

    10-K/A - Armada Hoffler Properties, Inc. (0001569187) (Filer)

    2/27/26 5:25:11 PM ET
    $AHH
    Real Estate
    Finance

    SEC Form 10-K filed by Armada Hoffler Properties Inc.

    10-K - Armada Hoffler Properties, Inc. (0001569187) (Filer)

    2/26/26 4:20:58 PM ET
    $AHH
    Real Estate
    Finance

    Fortress Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Fortress Biotech, Inc. (0001429260) (Filer)

    2/23/26 8:35:50 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHH
    $FBIO
    $FRD
    $LGF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Armada Hoffler Properties with a new price target

    Jefferies initiated coverage of Armada Hoffler Properties with a rating of Buy and set a new price target of $8.00

    6/27/25 7:47:37 AM ET
    $AHH
    Real Estate
    Finance

    Scotiabank initiated coverage on Armada Hoffler Properties with a new price target

    Scotiabank initiated coverage of Armada Hoffler Properties with a rating of Sector Perform and set a new price target of $11.00

    1/28/25 7:55:14 AM ET
    $AHH
    Real Estate
    Finance

    Armada Hoffler Properties downgraded by Jefferies with a new price target

    Jefferies downgraded Armada Hoffler Properties from Buy to Hold and set a new price target of $11.00 from $13.00 previously

    7/15/24 7:25:47 AM ET
    $AHH
    Real Estate
    Finance

    $AHH
    $FBIO
    $FRD
    $LGF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President / CEO / Director Taylor Mike J bought $1,800 worth of shares (100 units at $18.00), increasing direct ownership by 0.05% to 222,266 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    2/25/26 3:40:59 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    Chief Operating Officer Chhibbar Gaurav bought $18,350 worth of shares (1,000 units at $18.35), increasing direct ownership by 2% to 51,000 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    2/23/26 3:46:13 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    President / CEO / Director Taylor Mike J bought $11,250 worth of shares (600 units at $18.75), increasing direct ownership by 0.27% to 222,166 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    2/20/26 1:41:11 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    $AHH
    $FBIO
    $FRD
    $LGF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President / CEO / Director Taylor Mike J bought $1,800 worth of shares (100 units at $18.00), increasing direct ownership by 0.05% to 222,266 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    2/25/26 3:40:59 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    Chief Operating Officer Chhibbar Gaurav bought $18,350 worth of shares (1,000 units at $18.35), increasing direct ownership by 2% to 51,000 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    2/23/26 3:46:13 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    President / CEO / Director Taylor Mike J bought $11,250 worth of shares (600 units at $18.75), increasing direct ownership by 0.27% to 222,166 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    2/20/26 1:41:11 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    $AHH
    $FBIO
    $FRD
    $LGF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

    ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d

    2/23/26 8:00:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHH
    $FBIO
    $FRD
    $LGF
    Financials

    Live finance-specific insights

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Armada Hoffler Unveils Bold New Strategic Direction to Drive Long-Term Shareholder Value and Launches as AH Realty Trust

    Executing a fundamental business restructuring to eliminate complexity, strengthen the balance sheet, and relentlessly focus on operating a streamlined real estate platform: Exiting the multifamily property sector to unlock embedded value, reduce leverage and sharpen focus on retail and office properties Divesting construction and real estate financing businesses Aligning long-term performance with shareholder value creation through redesigned executive compensation structures Launching AH Realty Trust, effective March 2, 2026, a new corporate identity that reflects the fundamental restructuring of the business Launching under new NYSE tickers, AHRT and AHRT-PrA, effective March 2, 2026 VI

    2/16/26 4:09:37 PM ET
    $AHH
    Real Estate
    Finance

    $AHH
    $FBIO
    $FRD
    $LGF
    Leadership Updates

    Live Leadership Updates

    View All

    Armada Hoffler Announces Appointment of Shawn J. Tibbetts as Chairman of the Board of Directors

    VIRGINIA BEACH, Va., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Armada Hoffler (NYSE:AHH) today announced that its Board of Directors unanimously voted to appoint Shawn J. Tibbetts as Chairman of the Board, effective January 1, 2026. This action completes the last phase of the planned succession changes initiated in 2024. In addition to his new role, Tibbetts will continue leading the Company as President and Chief Executive Officer. A seasoned global executive, Tibbetts brings more than two decades of leadership experience in real estate, large-scale infrastructure, and operations, including leading complex business transformations. Since joining Armada Hoffler in 2019, he has strengthened the pe

    10/16/25 6:15:00 AM ET
    $AHH
    Real Estate
    Finance

    Friedman Industries Appoints Gaurav Chhibbar as Chief Operating Officer

    LONGVIEW, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Friedman Industries, Incorporated (NASDAQ/GS: FRD) is pleased to announce the appointment of Gaurav Chhibbar as the Company's new Chief Operating Officer (COO) effective July 10, 2025. Gaurav joins Friedman Industries with a distinguished career in operations excellence, strategy, corporate finance, and M&A due diligence. Gaurav has built extensive experience through meaningful roles at Boston Consulting Group Inc., and prior to that, at Metal Edge Partners LLC and Cargill Inc. At Boston Consulting Group, he supported and led numerous efforts for clients across various sectors, including financial sponsors, private equity, family-owned, a

    7/14/25 8:30:36 AM ET
    $FRD
    Steel/Iron Ore
    Industrials

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHH
    $FBIO
    $FRD
    $LGF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Friedman Industries Inc.

    SC 13G/A - FRIEDMAN INDUSTRIES INC (0000039092) (Subject)

    11/13/24 10:49:47 AM ET
    $FRD
    Steel/Iron Ore
    Industrials

    Amendment: SEC Form SC 13G/A filed by Armada Hoffler Properties Inc.

    SC 13G/A - Armada Hoffler Properties, Inc. (0001569187) (Subject)

    11/1/24 3:13:50 PM ET
    $AHH
    Real Estate
    Finance

    SEC Form SC 13G filed by Fortress Biotech Inc.

    SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care